Zentek Announces Partnership with FTI Consulting to Support U.S. Expansion Strategy

Rhea-AI Summary

Zentek Ltd. (NASDAQ: ZTEK) has partnered with FTI Consulting to aid its U.S. market expansion, focusing on the regulatory approval process for its ZenGUARD™ nanotechnology. This partnership aims to navigate the complicated federal regulations and potentially launch ZenGUARD™, which boasts 99% antimicrobial activity, including against COVID-19. This announcement follows Zentek's recent debut on the NASDAQ, enhancing its strategy to commercialize innovative healthcare solutions.

Positive

• Partnership with FTI Consulting to assist in U.S. market entry and regulatory navigation.
• ZenGUARD™ has demonstrated 99% antimicrobial efficacy against COVID-19.

Negative

• None.

GUELPH, ON / ACCESSWIRE / March 30, 2022 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSX-V:ZEN), a Canadian intellectual property development and commercialization company, announces its partnership with FTI Consulting (Government Affairs), LLC ("FTI"), a Washington, D.C. based global advisory firm, to support its efforts to bring ZenGUARD™ and its other technologies to the U.S.

"Zentek's partnership with FTI will help the Company expand its presence in the U.S. market in a number of ways, including with the regulatory approval process for our nanotechnologies," said Greg Fenton, CEO of Zentek. "We are excited to work with FTI to expand Zentek's presence into the U.S."

Bryan Zumwalt, Senior Managing Director and head of FTI Consulting Government Affairs practice said, "We are delighted to work with Zentek to help this incredibly exciting company navigate the complex federal regulatory environment here in the U.S. and win approval of its innovative technologies, beginning with ZenGUARD™, which we believe can be a transformative and scalable tool for infection control in the U.S."

The announcement of the engagement with the U.S. based consulting firm comes a week after Zentek began trading common stock on the Nasdaq under the symbol ZTEK.

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating shown to have 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.

About FTI Consulting

FTI Consulting, Inc. is a global business advisory firm dedicated to helping organizations manage change, mitigate risk and resolve disputes: financial, legal, operational, political & regulatory, reputational and transactional. With more than 6,600 employees located in 29 countries, FTI Consulting professionals work closely with clients to anticipate, illuminate and overcome complex business challenges and make the most of opportunities. The Company generated $2.46 billion in revenues during fiscal year 2020. In certain jurisdictions, FTI Consulting's services are provided through distinct legal entities that are separately capitalized and independently managed. For more information, visit www.fticonsulting.com and connect with us on Twitter (@FTIConsulting), Facebook and LinkedIn.

For further information:
Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com

To find out more about Zentek Ltd., please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at http://www.sedar.com/.

Forward-Looking Statements

This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Zentek Ltd.

View source version on accesswire.com:
https://www.accesswire.com/695195/Zentek-Announces-Partnership-with-FTI-Consulting-to-Support-US-Expansion-Strategy

FAQ

What is Zentek Ltd.'s recent partnership about?

Zentek Ltd. has partnered with FTI Consulting to facilitate its expansion into the U.S. market and to navigate federal regulatory processes for its technologies.

What product is Zentek focusing on with its new partnership?

Zentek is focusing on its ZenGUARD™ technology, which shows 99% antimicrobial activity, including effectiveness against COVID-19.

When did Zentek Ltd. start trading on NASDAQ?

Zentek Ltd. began trading on NASDAQ under the symbol ZTEK just a week prior to the announcement of its partnership with FTI Consulting.